Evidence map›Paper›PMID 35194179›Full record

ArticleProstate cancer and prostatic diseases2022

Substantial Gleason reclassification in Black men with national comprehensive cancer network low-risk prostate cancer - A propensity score analysis.

Shivanshu Awasthi, Brandon A Mahal, Jong Y Park, Jordan H Creed, Vonetta L Williams, Asmaa Elkenawi, Sylvester O Meadows, Julio M Pow-Sang, Grace Lu-Yao, Wm Kevin Kelly and 4 more

Abstract read
In one paragraph

Article in Prostate cancer and prostatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shivanshu AwasthiDepartment of Cancer Epidemiology, H Lee Moffitt Cancer Center, Tampa, FL, USA.ORCID 0000-0003-4175-3212
Brandon A MahalUniversity of Miami Miller School of Medicine (MSOM)-Sylvester Comprehensive Cancer Center (SCCC), Miami, FL, USA.ORCID 0000-0001-5406-3232
Jong Y ParkDepartment of Cancer Epidemiology, H Lee Moffitt Cancer Center, Tampa, FL, USA.ORCID 0000-0002-6384-6447
Jordan H CreedDepartment of Health Informatics, H Lee Moffitt Cancer Center, Tampa, FL, USA.
Vonetta L WilliamsCollaborative Data Services Core, H Lee Moffitt Cancer Center, Tampa, FL, USA.
Asmaa ElkenawiDepartment of Cancer Epidemiology, H Lee Moffitt Cancer Center, Tampa, FL, USA.
Sylvester O MeadowsThe City University of New York, CUNY, New York, NY, USA.
Julio M Pow-SangDepartment of Genitourinary Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USA.ORCID 0000-0003-1827-6585
Grace Lu-YaoThomas Jefferson University and Sidney Kimmel Cancer Center, Philadelphia, PA, USA.ORCID 0000-0002-6017-9175
Wm Kevin KellyThomas Jefferson University and Sidney Kimmel Cancer Center, Philadelphia, PA, USA.
Damaris-Lois Y LangCUNY Academy for the Humanities and Sciences, New York, NY, USA.
Janice ZgiborCollege of Public Health University of South Florida, Tampa, FL, USA.
Timothy R RebbeckHarvard T.H Chan School of Public Health and Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-4799-1900
Kosj YamoahDepartment Cancer Epidemiology and Radiation Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USA. Kosj.Yamoah@moffitt.org.ORCID 0000-0001-9055-3538

Funding

Precision Interception of Aggressive Prostate Cancer in African American MenP20CA233255 · NCI · DANA-FARBER CANCER INST · PI REBBECK, TIMOTHY R · 2018 to 2020
$3.2M
NCI NIH HHS P20 CA233255
6 · The paper itself

Abstract

backgroundEmerging evidence suggests that a subset of Black men with National Comprehensive Cancer Network (NCCN) low-risk prostate cancer (PCa) may harbor high volume and genomically aggressive disease. However, limited, and ambiguous research exist to evaluate the risk of extreme Gleason reclassification in Black men with low-risk PCa.

methodsThis retrospective cohort study included 45,674 low-risk PCa patients who underwent prostatectomy and were not on active surveillance, from National Cancer Database (NCDB). A propensity score matched-pair design was employed, and the final cohort was limited to 1:1 matched 12,340 patients. Gleason score reclassification was used as primary endpoint. As such, any migration to pathologic Gleason score ≥7(3 + 4) was identified as overall, whereas migration to ≥7(4 + 3) was defined as extreme reclassification. A conditional Poisson regression model was used to estimate the risk of reclassification. Whereas spline model was used to estimate the impact of increasing time to treatment as a non-linear function on Gleason reclassification between race group.

resultsUpon matching there were no differences in the baseline characteristics between race groups. In a matched cohort, higher proportion of low-risk Black men (6.6%) reported extreme reclassification to pathologic Gleason score than White men (5.0%), p < 0.001. In a conditional Poisson regression model adjusted for time to treatment, the risk of overall (RR = 1.09, 95% CI, 1.05-1.13, p < 0.001) and extreme (RR = 1.30, 95% CI, 1.12-1.50, p = 0.004) reclassification was significantly higher in Black men as compared to their White counterpart. In spline model, the probability of Gleason reclassification in Black men was elevated with increasing time to treatment, especially after 180 days (53% vs. 43% between Black and White men).

conclusionRisk of Gleason score reclassification is disparately elevated in Black men with low-risk PCa. Furthermore, time to treatment can non-linearly impact Gleason reclassification in Black men.

Indexed as

Prostatic NeoplasmsBlack PeopleHumansMaleNeoplasm GradingPropensity ScoreProstatectomyProstate-Specific AntigenRetrospective StudiesProstate-Specific Antigen

Identifiers

PMID35194179
PMCPMC9838824

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.